News

Tisagenlecleucel Shows Durable Five-Year Remissions in Pediatric and Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

08/19/2026

Emily Estrada

Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...

Five-year results from the phase...

08/19/2026

Oncology

News

Inotuzumab Ozogamicin Demonstrates High Response Rates in Pediatric Patients With Very High-Risk First Relapse B-Cell Acute Lymphoblastic Leukemia

07/24/2026

Emily Estrada

Results from cohort 3 of the phase 1/2 ITCC-059 trial demonstrated that inotuzumab ozogamicin produced high response rates with a manageable safety profile in pediatric patients with very high-risk first relapse of B-cell acute lymphoblastic...

Results from cohort 3 of the...

07/24/2026

Oncology

News

CD5 Inhibition Enhances Activity of T-Cell Engagers Across Tumor Types

06/16/2026

Stephanie Holland

Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.

Results from a translational...

06/16/2026

Oncology

News

Blinatumomab Improves Survival and Reduces Toxicity in Pediatric Patients With High-Risk B-Acute Lymphoblastic Leukemia

06/15/2026

Stephanie Holland

Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...

Results from a phase 2 study...

06/15/2026

Oncology

News

Fractionated Varnimcabtagene Autoleucel Induces High Rates of MRD-Negative Complete Remission in Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

02/04/2026

Stephanie Holland

Results from the phase 2 CART19-BE-02 trial demonstrated that varnimcabtagene autoleucel, a CD19-directed CAR T-cell therapy incorporating adaptive fractionated dose escalation, induced high rates of deep remission with a manageable safety...

Results from the phase 2...

02/04/2026

Oncology

Conference Coverage

Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia

01/22/2026

Matthew Connor, MD

Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.

Matthew Connor, MD, highlighted...

01/22/2026

Oncology

Conference Coverage

IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia

01/16/2026

Matthew Connor, MD

Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.

Matthew Connor, MD, reported...

01/16/2026

Oncology

Videos

Exploring the Optimal Role of Transplant for Patients with Acute Lymphoblastic Leukemia

10/14/2025

Alexandra Gomez Arteaga, MD

Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.

Alexandra Gomez Arteaga, MD,...

10/14/2025

Oncology

Conference Coverage

Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia

06/29/2025

Elias Jabbour, MD

At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.

At the 2025 Great Debates in...

06/29/2025

Oncology

Conference Coverage

Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL

06/28/2025

Shira Dinner, MD

Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.

Shira Dinner, MD, debates the...

06/28/2025

Oncology

Recent News

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology